secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coya Therapeutics, Inc. (COYA)
CIK:        0001835022
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0000950170-24-121833
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coya Therapeutics Q3 net loss $4.0M, cash $39.8M post-raise; positive AD data, new CEO
--------------------------------------------------------------------------------

- Net loss $4.0M in Q3 2024 (vs $3.4M prior); cash $31.1M (Sep) rose to $39.8M after capital raise.
- Positive LD IL-2 data in mild-moderate Alzheimer's from investigator-initiated Phase 2 presented at CTAD24; patents filed for COYA 301/GLP-1 combo.
- Arun Swaminathan appointed CEO effective Nov 1, 2024; Howard Berman transitions to Executive Chairman.
- Aligned with FDA on non-clinical data for COYA-302 Phase 2b ALS trial; eligible for $8.4M milestone from Dr. Reddy's upon IND acceptance and dosing.
- 2025 catalysts: additional AD data Q1, ALS biomarker data Q2, FTD data 2H, and COYA-302 IND for FTD expected in 2H.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835022/000095017024121833/0000950170-24-121833-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835022/000095017024121833/coya-20241106.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-121833

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer